Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance

AbCellera Biologics IncTrade
Vanguard Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Vanguard Growth Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $9.31 (market cap $2.85B), while Vanguard Growth Index Fund ETF trades at $89.5. Which is the better fit depends on your goals.

ABCLVUG
Market Cap
$2.85B
Sector
HealthSector/Thematic
52-Week High
$9.34$90.29
52-Week Low
$2.78$70.00
Enterprise Value
$2.45B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Vanguard Growth Index Fund ETF

Vanguard Growth ETF (VUG) trades at $89.4, up 0.81% today, with a bullish technical signal driven by strong moving average support. Recent news highlights significant institutional buying interest, with multiple firms increasing stakes by over 500% in Q2 2026. The ETF focuses on large-cap growth stocks, offering broad exposure to innovative US companies.

Outlook remains positive given institutional accumulation and growth stock momentum, though an RSI of 95.06 on a 6-day basis indicates potential overbought conditions. Key risks include market volatility and sensitivity to interest rate changes, but long-term growth prospects appear solid based on historical performance and sector trends.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Vanguard Growth Index Fund ETF

VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.

Read more on VUG